Merus BV (MRUS) - Total Liabilities
Based on the latest financial reports, Merus BV (MRUS) has total liabilities worth $110.36 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Merus BV operating cash flow efficiency to assess how effectively this company generates cash.
Merus BV - Total Liabilities Trend (2012–2024)
This chart illustrates how Merus BV's total liabilities have evolved over time, based on quarterly financial data. Check Merus BV asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Merus BV Competitors by Total Liabilities
The table below lists competitors of Merus BV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ZEEKR Intelligent Technology Holding Limited
NYSE:ZK
|
USA | $82.65 Billion |
|
Yanzhou Coal Mining Company Limited
F:YZCA
|
Germany | €291.25 Billion |
|
Lincoln National Corporation
NYSE:LNC
|
USA | $395.95 Billion |
|
Shenzhen Honor Electronic Co Ltd
SHE:300870
|
China | CN¥2.93 Billion |
|
Elisa Oyj
HE:ELISA
|
Finland | €2.26 Billion |
|
MYR Group Inc
NASDAQ:MYRG
|
USA | $970.61 Million |
|
Hellenic Telecommunications Organization S.A
AT:HTO
|
Greece | €3.07 Billion |
|
Rigetti Computing Inc
NASDAQ:RGTI
|
USA | $67.09 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Merus BV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Merus BV (MRUS) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Merus BV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Merus BV (2012–2024)
The table below shows the annual total liabilities of Merus BV from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $134.77 Million | +35.92% |
| 2023-12-31 | $99.15 Million | -23.43% |
| 2022-12-31 | $129.49 Million | -7.77% |
| 2021-12-31 | $140.40 Million | +8.88% |
| 2020-12-31 | $128.95 Million | -2.36% |
| 2019-12-31 | $132.08 Million | -8.83% |
| 2018-12-31 | $144.87 Million | -18.91% |
| 2017-12-31 | $178.65 Million | +343.77% |
| 2016-12-31 | $40.26 Million | +411.99% |
| 2015-12-31 | $7.86 Million | -8.91% |
| 2014-12-31 | $8.63 Million | +31.28% |
| 2013-12-31 | $6.58 Million | +97.98% |
| 2012-12-31 | $3.32 Million | -- |
About Merus BV
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the… Read more